These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 28364695)
1. The influence of a single and chronic administration of venlafaxine on tramadol pharmacokinetics in a rabbit model. Szkutnik-Fiedler D; Grabowski T; Balcerkiewicz M; Michalak M; Pilipczuk I; Wyrowski Ł; Urjasz H; Grześkowiak E Pharmacol Rep; 2017 Jun; 69(3):555-559. PubMed ID: 28364695 [TBL] [Abstract][Full Text] [Related]
2. Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2. Arakawa R; Stenkrona P; Takano A; Svensson J; Andersson M; Nag S; Asami Y; Hirano Y; Halldin C; Lundberg J Int J Neuropsychopharmacol; 2019 Apr; 22(4):278-285. PubMed ID: 30649319 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. Krieger CA; Cunningham JL; Reid JM; Langman LJ; Grothe KB; Clark MM; Dierkhising RA Pharmacotherapy; 2017 Nov; 37(11):1374-1382. PubMed ID: 28845898 [TBL] [Abstract][Full Text] [Related]
4. A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. Bodalia B; McDonald CJ; Smith KJ; O'Brien C; Cousens L J Pain Symptom Manage; 2003 Feb; 25(2):142-9. PubMed ID: 12590030 [TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling for Substitutability Analysis of Venlafaxine Hydrochloride Extended-Release Formulations Using Different Release Mechanisms: Osmotic Pump Versus Openable Matrix. Lin HP; Sun D; Zhang X; Wen H J Pharm Sci; 2016 Oct; 105(10):3088-3096. PubMed ID: 27449228 [TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of a once-daily tramadol extended-release tablet and an immediate-release reference product following single-dose and multiple-dose administration. Karhu D; Fradette C; Potgieter MA; Ferreira MM; Terblanché J J Clin Pharmacol; 2010 May; 50(5):544-53. PubMed ID: 20051587 [TBL] [Abstract][Full Text] [Related]
7. Biopharmaceutical evaluation of new slow release tablets obtained by hot tableting of coated pellets with tramadol hydrochloride. Szkutnik-Fiedler D; Sawicki W; Balcerkiewicz M; Mazgalski J; Grabowski T; Grześkowiak E Acta Pol Pharm; 2014; 71(5):813-20. PubMed ID: 25362810 [TBL] [Abstract][Full Text] [Related]
8. Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay. Islin J; Munkboel CH; Styrishave B Toxicol In Vitro; 2018 Mar; 47():63-71. PubMed ID: 29100959 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Teng R; Kujacic M; Hsia J Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798 [TBL] [Abstract][Full Text] [Related]
10. In vitro - in vivo evaluation of a new oral dosage form of tramadol hydrochloride--controlled-release capsules filled with coated pellets. Szkutnik-Fiedler D; Balcerkiewicz M; Sawicki W; Grabowski T; Grześkowiak E; Mazgalski J; Urjasz H Acta Pol Pharm; 2014; 71(3):469-75. PubMed ID: 25265827 [TBL] [Abstract][Full Text] [Related]
20. Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Klotz U Arzneimittelforschung; 2003; 53(10):681-7. PubMed ID: 14650359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]